Abstract
Combinations of different drug concentrations of CLB + FAMP and CLB + 2-CDA were synergistic in, respectively, 42.9% and 34.8%. At leukemic cell survival < or = 50%, 16.4% and 23.4% of all combinations were synergistic in the 2-CDA and FAMP groups, respectively. A significantly higher mean value of antagonistic interactions was observed in the 2-CDA group (p = 0.037).
MeSH terms
-
Antimetabolites, Antineoplastic / pharmacology*
-
Antineoplastic Agents, Alkylating / pharmacology*
-
Chlorambucil / pharmacology*
-
Cladribine / pharmacology*
-
Drug Screening Assays, Antitumor
-
Drug Synergism
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
-
Neoplastic Stem Cells / drug effects*
-
Tumor Cells, Cultured / drug effects
-
Vidarabine / analogs & derivatives*
-
Vidarabine / pharmacology
Substances
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents, Alkylating
-
Chlorambucil
-
Cladribine
-
Vidarabine
-
fludarabine